BE560809A - - Google Patents

Info

Publication number: BE560809A
Authority: BE; Belgium
Prior art keywords: salts; anions; salt; forming; water
Prior art date

Application number

Other languages

English (en)

French (fr)

Publication of BE560809A publication Critical patent/BE560809A/fr

Links

150000003839 salts Chemical class 0.000 claims description 36
239000000243 solution Substances 0.000 claims description 35
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
229920000642 polymer Polymers 0.000 claims description 23
238000002360 preparation method Methods 0.000 claims description 21
150000001450 anions Chemical class 0.000 claims description 15
229910052783 alkali metal Inorganic materials 0.000 claims description 11
150000001340 alkali metals Chemical class 0.000 claims description 11
239000002253 acid Substances 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
239000000126 substance Substances 0.000 claims description 8
229940079593 drug Drugs 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 6
230000008569 process Effects 0.000 claims description 5
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
230000001225 therapeutic effect Effects 0.000 claims description 4
230000003115 biocidal effect Effects 0.000 claims description 2
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
150000001447 alkali salts Chemical class 0.000 claims 1
229960004909 aminosalicylic acid Drugs 0.000 claims 1
239000012895 dilution Substances 0.000 claims 1
238000010790 dilution Methods 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000008174 sterile solution Substances 0.000 claims 1
230000002195 synergetic effect Effects 0.000 claims 1
159000000000 sodium salts Chemical class 0.000 description 13
239000000047 product Substances 0.000 description 10
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
239000007864 aqueous solution Substances 0.000 description 8
239000002585 base Substances 0.000 description 8
229920000193 polymethacrylate Polymers 0.000 description 8
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
229910052708 sodium Inorganic materials 0.000 description 7
239000011734 sodium Substances 0.000 description 7
-1 stréptothricin Natural products 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000004108 freeze drying Methods 0.000 description 6
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 5
238000001914 filtration Methods 0.000 description 5
229960005322 streptomycin Drugs 0.000 description 5
229960002385 streptomycin sulfate Drugs 0.000 description 5
229920000856 Amylose Polymers 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
230000000694 effects Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
CZWJCQXZZJHHRH-YCRXJPFRSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O CZWJCQXZZJHHRH-YCRXJPFRSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
229960001162 dihydrostreptomycin sulfate Drugs 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
231100001231 less toxic Toxicity 0.000 description 3
229920002521 macromolecule Polymers 0.000 description 3
OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 3
229940053050 neomycin sulfate Drugs 0.000 description 3
238000006116 polymerization reaction Methods 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000001954 sterilising effect Effects 0.000 description 3
238000004659 sterilization and disinfection Methods 0.000 description 3
229950001272 viomycin Drugs 0.000 description 3
AQONYROJHRNYQQ-QMAPKBLTSA-N (3s)-3,6-diamino-n-[(3s,6z,9s,12s,15s)-3-[(4s,6r)-2-amino-4-hydroxy-1,4,5,6-tetrahydropyrimidin-6-yl]-6-[(carbamoylamino)methylidene]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentazacyclohexadec-15-yl]hexanamide;sulfuric acid Chemical compound OS(O)(=O)=O.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(N)=N[C@@H](O)C1 AQONYROJHRNYQQ-QMAPKBLTSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 2
229920002527 Glycogen Polymers 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
108010015940 Viomycin Proteins 0.000 description 2
OZKXLOZHHUHGNV-UHFFFAOYSA-N Viomycin Natural products NCCCC(N)CC(=O)NC1CNC(=O)C(=CNC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC1=O)C2CC(O)NC(=N)N2 OZKXLOZHHUHGNV-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
229930013930 alkaloid Natural products 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
230000003444 anaesthetic effect Effects 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000010908 decantation Methods 0.000 description 2
229960002086 dextran Drugs 0.000 description 2
229960000633 dextran sulfate Drugs 0.000 description 2
229960002222 dihydrostreptomycin Drugs 0.000 description 2
ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 2
125000004185 ester group Chemical group 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229940096919 glycogen Drugs 0.000 description 2
JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
229960005195 morphine hydrochloride Drugs 0.000 description 2
XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
150000004804 polysaccharides Chemical class 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
229940068984 polyvinyl alcohol Drugs 0.000 description 2
235000019422 polyvinyl alcohol Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000007127 saponification reaction Methods 0.000 description 2
230000007928 solubilization Effects 0.000 description 2
238000005063 solubilization Methods 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 2
150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
GXFAIFRPOKBQRV-GHXCTMGLSA-N viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 description 2
FVVDKUPCWXUVNP-UHFFFAOYSA-M Aminosalicylate sodium anhydrous Chemical compound [Na+].NC1=CC=C(C([O-])=O)C(O)=C1 FVVDKUPCWXUVNP-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
229920001938 Vegetable gum Polymers 0.000 description 1
125000004036 acetal group Chemical group 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003368 amide group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
150000007656 barbituric acids Chemical class 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
150000001991 dicarboxylic acids Chemical class 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
125000001033 ether group Chemical group 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
LVHBHZANLOWSRM-UHFFFAOYSA-N itaconic acid Chemical class OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
125000005395 methacrylic acid group Chemical class 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
VIJMMQUAJQEELS-UHFFFAOYSA-N n,n-bis(ethenyl)ethenamine Chemical compound C=CN(C=C)C=C VIJMMQUAJQEELS-UHFFFAOYSA-N 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
125000002560 nitrile group Chemical group 0.000 description 1
150000002825 nitriles Chemical class 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
238000006068 polycondensation reaction Methods 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BE560809D BE560809A (de)

Publications (1)

Publication Number	Publication Date
BE560809A true BE560809A (de)

Family

ID=182975

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE560809D BE560809A (de)

Country Status (1)

Country	Link
BE (1)	BE560809A (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2134503A1 (de) *	1971-04-26	1972-12-08	Sasuco Sa
EP0211268A3 (en) *	1985-07-19	1988-01-20	Vincenzo Zappia	Slow-release topical formulations

0
- BE BE560809D patent/BE560809A/fr unknown

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2134503A1 (de) *	1971-04-26	1972-12-08	Sasuco Sa
EP0211268A3 (en) *	1985-07-19	1988-01-20	Vincenzo Zappia	Slow-release topical formulations

Publication	Publication Date	Title
US4699927A (en)	1987-10-13	Anticonvulsant valproic acid salts
ES2320439T3 (es)	2009-05-22	Taxanos unidos covalentemente al acido hialuronico o a derivados del acido hialuronico.
DE3885317T2 (de)	1994-03-03	Makromolekulare Platin-Antitumorverbindungen.
DE69730352T2 (de)	2005-09-08	Verfahren zur herstellung eines arzneimittelkomplexes
DE69903329T2 (de)	2003-07-10	Verfahren zur herstellung einer eisen-dextran verbindung
EP1480681B1 (de)	2011-04-20	Kopplung niedermolekularer substanzen an hydroxyalkylstärke
DE69629114T2 (de)	2004-04-22	Ionisches molekularkonjugat von n-acylierten poly(2-amino-2deoxy-d-glucose) und polypeptide-derivaten
DE69734607T2 (de)	2006-08-03	Langwirkende arzneistoffe und diese enthaltende arzneimittel
DE69232790T2 (de)	2003-07-24	Wasserunlösliche derivate von polyanionischen polysacchariden
DE69708304T2 (de)	2002-07-25	Vernetzte copolymere auf der basis von polycarbonsäurepolymeren
DE3217315C2 (de)	1986-05-22	Arzneimittelzubereitungen mit einem Gehalt an Oxicam-Derivaten
US4409233A (en)	1983-10-11	Highly concentrated preparations of dopa compounds
CH616080A5 (de)	1980-03-14
JPS5885813A (ja)	1983-05-23	吸収性良好な製剤
CN1165315C (zh)	2004-09-08	关节性疾病治疗剂
DE602005004014T2 (de)	2008-12-11	Verfahren zur solubilisierung von peptid-mischungen
DE69316758T2 (de)	1998-08-27	Selbstvernetztes gellangummi
DE69513767T2 (de)	2000-08-10	Pharmazeutische Zusammensetzung in Form eines Gels mit Chondroitinsulfat in Salzform zur oralen Verabreichung
DE2635843A1 (de)	1977-02-24	Injizierbare waessrige acetylsalicylsaeureloesung
DE69703994T2 (de)	2001-05-23	Parenteral injizierbare Lösungen enthaltend Piroxicam
EP0593605A1 (de)	1994-04-27	Verfahren zur herstellung von stärkeestern für klinische, insbesondere parenterale anwendung
CH666273A5 (de)	1988-07-15	Verfahren zur herstellung einer neuen haemin-komplexverbindung und diese als wirksubstanz enthaltende pharmazeutische zubereitungen.
KR102665664B1 (ko)	2024-05-10	황산화 다당류의 유도체 및 이의 제조 방법, 변형 방법 및 용도
EP0026746B1 (de)	1985-04-10	Kombinationspräparate zur Anwendung in einem Verfahren zur Steigerung der Wirkung von Antibiotika, antibiotische Präparate mit gesteigerter Wirksamkeit und Verfahren zu deren Herstellung
DE19912436A1 (de)	2000-09-21	Ibuprofen-Lösung

BE560809A - - Google Patents

Info

Links

Classifications

Landscapes

Publications (1)

Family

ID=182975

Family Applications (1)

Country Status (1)

Cited By (2)

Cited By (2)

Similar Documents